Results

1–3 of 3 results for Macular telangiectasia type 2

Pooled Clinical Trial Safety Data of Neurotrophic Factorâ€“Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
Paul S. Bernstein, MD, PhD
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024